FlatWing Denied Atty Fees In Patent Fight With Pfizer Unit
A federal magistrate judge has recommended against shifting nearly $690,000 in fees and expenses to Pfizer unit Anacor Pharmaceuticals from a company that challenged Anacor's patent for a toenail fungus treatment,...To view the full article, register now.
Already a subscriber? Click here to view full article